Verastem Yönetim

Yönetim kriter kontrolleri 1/4

Verastem CEO'su Dan Paterson, Jun2019 tarihinde atandı, in görev süresi 5.42 yıldır. in toplam yıllık tazminatı $ 3.63M olup, şirket hissesi ve opsiyonları dahil olmak üzere 15% maaş ve 85% ikramiyelerden oluşmaktadır. şirketin hisselerinin 0.094% ine doğrudan sahiptir ve bu hisseler $ 167.06K değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 1.6 yıl ve 3.2 yıldır.

Anahtar bilgiler

Dan Paterson

İcra Kurulu Başkanı

US$3.6m

Toplam tazminat

CEO maaş yüzdesi	15.0%
CEO görev süresi	5.4yrs
CEO sahipliği	0.09%
Yönetim ortalama görev süresi	1.6yrs
Yönetim Kurulu ortalama görev süresi	3.2yrs

Son yönetim güncellemeleri

Recent updates

CEO Tazminat Analizi

Dan Paterson'un ücretlendirmesi Verastem'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Sep 30 2024	n/a	n/a	-US$93m
Jun 30 2024	n/a	n/a	-US$89m
Mar 31 2024	n/a	n/a	-US$106m
Dec 31 2023	US$4m	US$545k	-US$87m
Sep 30 2023	n/a	n/a	-US$77m
Jun 30 2023	n/a	n/a	-US$75m
Mar 31 2023	n/a	n/a	-US$73m
Dec 31 2022	US$698k	US$470k	-US$74m
Sep 30 2022	n/a	n/a	-US$73m
Jun 30 2022	n/a	n/a	-US$78m
Mar 31 2022	n/a	n/a	-US$73m
Dec 31 2021	US$2m	US$460k	-US$71m
Sep 30 2021	n/a	n/a	-US$75m
Jun 30 2021	n/a	n/a	-US$39m
Mar 31 2021	n/a	n/a	-US$45m
Dec 31 2020	US$2m	US$467k	-US$68m
Sep 30 2020	n/a	n/a	-US$87m
Jun 30 2020	n/a	n/a	-US$130m
Mar 31 2020	n/a	n/a	-US$149m
Dec 31 2019	US$2m	US$445k	-US$149m

Tazminat ve Piyasa: Dan 'nin toplam tazminatı ($USD 3.63M ), US pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 1.48M ).

Tazminat ve Kazançlar: Dan şirketinin tazminatı, şirket kârsız olduğu sürece artırıldı.

CEO

Dan Paterson (63 yo)

5.4yrs

Görev süresi

US$3,626,857

Tazminat

Mr. Daniel W. Paterson, also known as Dan, serves as Chief Executive Officer Verastem, Inc. since August 1, 2023 and is its President of Verastem, Inc. since June 2019. He is Director of Verastem, Inc. sin...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Daniel Paterson	President	5.4yrs	US$3.63m	0.094% $ 167.1k
Daniel Calkins	CFO and Principal Accounting & Financial Officer	2.1yrs	US$622.56k	0.015% $ 27.0k
Richard Aldrich	Founder and Consultant	10.2yrs	US$114.77k	Veri yok
Robert Weinberg	Co-Founder & Chair of Scientific Advisory Board	no data	Veri yok	Veri yok
Piyush Gupta	Co-Founder	no data	Veri yok	Veri yok
Michelle Dipp	Co-Founder	no data	Veri yok	Veri yok
Jonathan Pachter	Chief Scientific Officer	8.6yrs	US$319.51k	Veri yok
Cathy Carew	Chief Organizational Effectiveness Officer	no data	Veri yok	Veri yok
Nate Sanburn	Chief Business Officer	less than a year	Veri yok	Veri yok
Michael Crowther	Chief Commercial & Strategy Officer	1.1yrs	Veri yok	Veri yok
Colleen Mockbee	Global Head of Regulatory Affairs & Development	less than a year	Veri yok	Veri yok
John Hayslip	Chief Medical Officer	less than a year	Veri yok	Veri yok

1.6yrs

Ortalama Görev Süresi

55.5yo

Ortalama Yaş

Deneyimli Yönetim: VSTM 'un yönetim ekibi deneyimli olarak kabul edilmiyor ( 1.6 yıl), bu da yeni bir ekibin varlığını gösteriyor.

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Daniel Paterson	President	1.3yrs	US$3.63m	0.094% $ 167.1k
Robert Weinberg	Co-Founder & Chair of Scientific Advisory Board	no data	Veri yok	Veri yok
Mario Sznol	Member of Scientific Advisory Board	no data	Veri yok	Veri yok
Michael Kauffman	Lead Independent Director	12yrs	US$124.29k	0.0012% $ 2.2k
Paul A. Bunn	Independent Director	3.4yrs	US$74.29k	0% $ 0
Eric Rowinsky	Independent Director	7.5yrs	US$89.29k	0% $ 0
John Johnson	Independent Director	4.6yrs	US$81.29k	0% $ 0
Robert Gagnon	Director	1.9yrs	US$64.29k	0.056% $ 100.5k
Channing Der	Member of Scientific Advisory Board	2.7yrs	Veri yok	Veri yok
Brian Stuglik	Director	7.2yrs	US$2.30m	0.22% $ 384.4k
Anil Kapur	Independent Director	2.1yrs	US$81.75k	0% $ 0
Michelle Robertson	Independent Director	3yrs	US$84.29k	0% $ 0

3.2yrs

Ortalama Görev Süresi

65yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: VSTM 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 3.2 yıldır).

Verastem Yönetim

Yönetim kriter kontrolleri 1/4

Anahtar bilgiler

Son yönetim güncellemeleri

Verastem Oncology Announces Executive Changes

Verastem, Inc., Annual General Meeting, May 23, 2024

Verastem Oncology Announces Executive Appointments

Verastem, Inc. Appoints Daniel Paterson as Class III Director

Verastem Oncology Announces Promotion of Dan Paterson to Chief Executive Officer, Effective August 1, 2023

-Verastem Oncology Appoints Karin Tollefson to Board of Directors

Recent updates

Verastem Oncology Completes Rolling NDA Submission to the FDA for Avutometinib Plus Defactinib as A Treatment for Recurrent KRAS Mutant Low-Grade Serous Ovarian Cancer

Verastem Oncology Announces Details for the Oral Presentation of the Mature RAMP 201 Data Evaluating Avutometinib Plus Defactinib in Recurrent Low-Grade Serous Ovarian Cancer at the IGCS 2024 Annual Meeting

Verastem Oncology Receives FDA Orphan Drug Designation for Avutometinib and Defactinib for the Treatment of Pancreatic Cancer

Verastem, Inc. has completed a Follow-on Equity Offering in the amount of $54.995002 million.

Verastem, Inc. has completed a Follow-on Equity Offering in the amount of $54.995002 million.

Verastem Oncology Announces First Patient Dosed with Gfh375/Vs-7375 in A Phase 1/2 Trial in China as Part of Collaboration with Genfleet Therapeutics

Verastem: Narrowed Market And Less Compelling Efficacy Warrant Rating Downgrade

Verastem Oncology Announces Positive Initial Interim Safety and Efficacy Results from RAMP 205 Trial Evaluating Avutometinib Plus Defactinib in Combination with Gemcitabine and Nab-paclitaxel in First-Line Metastatic Pancreatic Cancer

Verastem Oncology Announces Executive Changes

Verastem, Inc., Annual General Meeting, May 23, 2024

Verastem Oncology Outlines Key 2024 Strategic Priorities and Upcoming Catalysts for Advancing Avutometinib and Broader Pipeline in RAS Pathway-Driven Cancers

Verastem Oncology Announces Initiation of A Confirmatory Phase 3 Trial of Avutometinib and Defactinib in Recurrent Low-Grade Serous Ovarian Cancer

Verastem Oncology Announces the Launch of the New Healthcare Professional Component

Verastem, Inc. has filed a Follow-on Equity Offering in the amount of $6.510455 million.

Verastem Oncology Announces Executive Appointments

Verastem Oncology Announces Initial Results of RAMP 203 Trial of Avutometinib and LUMAKRAS™ in KRAS G12C-Mutant Non-Small Cell Lung Cancer

Verastem, Inc. Appoints Daniel Paterson as Class III Director

Verastem Oncology Announces Promotion of Dan Paterson to Chief Executive Officer, Effective August 1, 2023

Verastem Oncology Announces Design for Confirmatory Trial of Avutometinib and Defactinib in Recurrent Low-Grade Serous Ovarian Cancer

Verastem, Inc. has completed a Follow-on Equity Offering in the amount of $85.018462 million.

Verastem Oncology Announces 1-for-12 Reverse Stock Split to Satisfy the Price Requirement for Continued Listing on the Nasdaq Global Market

-Verastem Oncology Appoints Karin Tollefson to Board of Directors

Price target decreased by 9.3% to US$3.25

Price target decreased by 11% to US$3.79

Verastem, Inc. announced that it expects to receive $59.995963 million in funding from BVF Partners L.P.

Price target decreased by 8.5% to US$4.30

Verastem, Inc. announced that it expects to receive $60 million in funding

Verastem Oncology Appoints Rob Gagnon to the Board of Directors

Less than half of directors are independent

Consensus forecasts updated

Price target decreased to US$4.70

Price target decreased to US$4.75

Verastem Oncology Appoints Anil Kapur to Board of Directors

Verastem Oncology Announces RAMP VS-6766 Clinical Trials

Verastem: Moving Forward

Health Check: How Prudently Does Verastem (NASDAQ:VSTM) Use Debt?

Second quarter 2022 earnings released: US$0.12 loss per share (vs US$0.098 loss in 2Q 2021)

Verastem Non-GAAP EPS of -$0.11 in-line

Verastem: Looking Increasingly Attractive

Verastem, Inc.(NasdaqGM:VSTM) dropped from Russell 2000 Dynamic Index

Verastem Oncology Provides Update on RAMP 201 Study Evaluating VS-6766 +/- Defactinib in Low-Grade Serous Ovarian Cancer

Consensus forecasts updated

First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Price target decreased to US$5.40

Less than half of directors are independent

Verastem: Time To Take My Position Out Of Mothball

Price target decreased to US$5.50

Consensus forecasts updated

Verastem, Inc., Annual General Meeting, May 12, 2022

Less than half of directors are independent

No longer forecast to breakeven

Verastem, Inc. Announces Management Changes

Vectoring In On Verastem

CEO & Director recently sold US$53k worth of stock

Forecast to breakeven in 2024

Third quarter 2021 earnings released: US$0.13 loss per share (vs US$0.078 profit in 3Q 2020)

Verastem: Buying Opportunity Following Unjustified Sell-Off

Verastem Oncology Announces Updated Investigator-Sponsored Phase 1/2 FRAME Study Data of VS-6766 with Defactinib in Low-Grade Serous Ovarian Cancer Showing Encouraging Response Rates and Progression-Free Survival Presented at ESMO 2021

Consensus forecasts updated

No longer forecast to breakeven

Second quarter 2021 earnings released: US$0.098 loss per share (vs US$0.14 loss in 2Q 2020)

Forecast to breakeven in 2023

Verastem, Inc.(NasdaqGM:VSTM) dropped from Russell 3000E Value Index

CEO Tazminat Analizi

CEO

Görev süresi

Tazminat

Liderlik Ekibi

Ortalama Görev Süresi